Going non-viral

Why Generation Bio’s ceDNA vectors could treat diseases AAVs cannot

Generation Bio Co. aims to take gene therapies into pediatric and other indications where adeno-associated virus vectors have not been able to go.

The company is developing preclinical gene therapies that are encoded in eukaryotic closed-ended DNA (ceDNA) vectors, which are linear, double-stranded DNA molecules whose ends have been closed via covalent linkages.

Unlike adeno-associated virus (AAV) vectors, ceDNA vectors are not immunogenic. That could make Generation

Read the full 655 word article

User Sign In